All In MedTech

FDA Clearance Tracker · P930014-S126

AcrySof™ IQ Vivity™ Extended Vision, Toric Extended Vision, Extended Vision UV Absorbing, and Toric Extended Vision UV A

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 26, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 26, 2020

Approved

Time to decision

201 days

Received Aug 9, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P930014-S126
Device name
AcrySof™ IQ Vivity™ Extended Vision, Toric Extended Vision, Extended Vision UV Absorbing, and Toric Extended Vision UV A
Applicant location
Fort Worth, TX
Received
Aug 9, 2019
Decided
Feb 26, 2020
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P930014

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code POE

FDA's approval statement

As written in FDA's record.

The AcrySof IQ Vivity Extended Vision IOL Model DFT015 is indicated for primary implantation for the visual correction of aphakia in adult patients with < 1.00 D of preoperative corneal astigmatism, in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The AcrySof IQ Vivity IOL is intended for capsular bag placement only.The AcrySof IQ Vivity Toric Extended Vision IOL Models DFT315, DFT415, and DFT515 are indicated for primary implantation for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients with pre-existing corneal astigmatism, in whom a cataractous lens has been removed by extracapsular cataract extraction. The lenses mitigate the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lenses provide improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The AcrySof IQ Vivity Toric IOLs are intended for capsular bag placement only.The AcrySof IQ Vivity Extended Vision UV Absorbing IOL Model DAT015 is indicated for primary implantation for the visual correction of aphakia in adult patients with < 1.00 D of preoperative corneal astigmatism, in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The AcrySof IQ Vivity UV Absorbing IOL is intended for capsular bag placement only.The AcrySof IQ Vivity Toric Extended Vision UV Absorbing IOL Models DAT315, DAT415, and DAT515 are indicated for primary implantation for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients with pre-existing corneal astigmatism, in whom a cataractous lens has been removed by extracapsular cataract extraction. The lenses mitigate the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. The AcrySof IQ Vivity Toric UV Absorbing IOLs are intended for capsular bag placement only.

Source documents

Other decisions for Alcon Laboratories, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.